Related references
Note: Only part of the references are listed.Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Risk categories and refractory CLL in the era of chemoimmunotherapy
Thorsten Zenz et al.
BLOOD (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia
Giles Best et al.
LEUKEMIA & LYMPHOMA (2012)
Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
P. Dreger et al.
LEUKEMIA (2007)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
A Rosenwald et al.
BLOOD (2004)
Share Paper
